The standard (reasonable belief that the medicine "may" be effective) for EUA is lower than for approval (satisfactory proof that the medicine is effective) reflecting the emergency situation.
Hydroxychloroquine had EUA for COVID-19 until it was withdrawn. It remains an FDA approved medicine for malaria prevention, because the evidence showed it works for that and that did not change, but it did not have proof that it was effective when it received EUA for COVID-19, and it still didn't have such proof when the EUA was withdrawn.
New Zealand's medicines authority did not need an emergency process because New Zealand's civil government had resolved the emergency, albeit at considerable cost. They concluded that the vaccine under consideration (the Pfizer BioNTech vaccine) did by that point have proof of effectiveness.
In one sense our loss is their gain, they were able to guage the effectiveness of the vaccines on other people, who were in danger of death from COVID-19, to establish that it was safe to use on their own people who faced much less danger.
In New Zealand since they had elimination they didn't do emergency approval. They expedited their normal process, but since there were literally no people dying in New Zealand of COVID-19 they weren't losing anybody by waiting for their medicines agency to complete all the steps it would usually take at the pace necessary.
They're currently vaccinating their general population, having at first prioritised health workers and those at the border who might meet infected people in the course of their duties.
Obviously things look a bit different when you've got people dying every day, but the vaccine is the same, so if you'd be more confident that it was assessed without worrying about all the people dying meanwhile, New Zealand did that. Months ago.